Navigation Links
Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
Date:3/11/2008

sels with excellent

specificity. The high degree of selective targeting seen in the study

provides additional evidence of bavituximab's therapeutic potential.

Bavituximab Anti-Viral Program: During the third quarter, the company continued to advance its bavituximab HCV program and presented positive data at a key liver disease meeting.
-- Added The Johns Hopkins Hospital and a private clinic in Orange

County, California as additional clinical study sites for the HCV/HIV

co-infection study.

-- Presented final results from the Phase I multiple dose HCV trial at

the prestigious Annual Meeting of the American Association for the

Study of Liver Disease that showed bavituximab was well tolerated and

demonstrated encouraging signs of anti-viral activity.

Cotara(R) Glioblastoma Program: Peregrine continued to advance the Cotara brain cancer program.
-- Added additional study sites and continued patient dosing and

follow-up in the Cotara Phase II study in patients with glioblastoma

multiforme, the most deadly form of brain cancer. Eight sites are now

open for patient enrollment.

-- Added an additional site, the Barrow Neurological Institute (BNI) in

Phoenix, Arizona, to the ongoing Cotara dosimetry and dose

confirmation clinical study. BNI also participated in a previous

Cotara Phase II clinical trial.

-- Announced positive results from the first cohort of patients treated

in the Cotara dosimetry trial and from the initial patients treated in

the Cotara Phase II trial. Cotara appeared safe and well tolerated

with no dose-limiting adverse events, with continuing patients being

monitored for overall survival. Several patients in these studies

have lived longer than the six-month expected median survival time for

this patient po
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
2. Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
3. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
4. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
5. Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
6. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
7. Peregrine Pharmaceuticals to Announce Second Quarter FY 2008 Financial Results
8. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
9. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
10. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
11. Alseres Pharmaceuticals Presents Inosine and Dopamine Transporter (DAT) Blocker Preclinical Data at the American Society for Experimental NeuroTherapeutics (ASENT) Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... 2014 Scientists, researchers, and technologists will ... Laser Damage 2014 symposium. Marking its 46th year, ... will run 14-17 September. The event is sponsored by ... . , The premier conference for basic and applied ... optical materials will engage researchers and engineers from numerous ...
(Date:8/28/2014)... Earlier this month, a report ... with the U.S. Air Force on the performance of ... that this type of fuel made from mustard seeds, ... important to America’s Eco friendly future. In fact, every ... to become independent of foreign oil over the next ...
(Date:8/28/2014)... August 28, 2014 Supplementing their ... a promotion for Eppendorf Safe Lock Centrifuge ... purchase the highest quality tubes at an affordable ... for customers doing chemical, medical, pharmaceutical, and life ... are not regularly able to afford Eppendorf products. ...
(Date:8/27/2014)... 27, 2014 Varian Medical Systems today ... current Salt Lake City manufacturing facility and allow for ... to ultimately create 1,000 new full time jobs in ... “Utah is home to hardworking people with immense engineering ... with Varian’s success in the manufacturing of our state-of-the-art ...
Breaking Biology Technology:Laser Damage to Draw Researchers, Engineers, Scientists to 46th Annual Conference 2Laser Damage to Draw Researchers, Engineers, Scientists to 46th Annual Conference 3Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 2Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 3Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 4Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 5Eppendorf Safe Lock Centrifuge Tube Promotion Now Available at Major Pipette Distributor Pipette.com 2Eppendorf Safe Lock Centrifuge Tube Promotion Now Available at Major Pipette Distributor Pipette.com 3Varian Medical Systems Groundbreaking on Facility Expansion Triggers Influx of New Jobs to Salt Lake 2Varian Medical Systems Groundbreaking on Facility Expansion Triggers Influx of New Jobs to Salt Lake 3
... a leading supplier of broadband technology and biometrics software,announced ... extension to,the program originally authorized on August 28, 2007 ... to $5 million worth of shares of,the Company,s common ... December,31, 2009 at prevailing market prices. The Board of ...
... Transgenomic, Inc. (OTC,Bulletin Board: TBIO) today announced financial ... financial results are presented in,the tables that follow., ... were $5.4 million during the third,quarter of 2008, compared ... profit from continuing operations was $2.9 million or 54,percent ...
... NVAX ) a clinical-stage vaccine company, announced today that ... presenting at,the Oppenheimer 19th Annual Healthcare Conference at 12:00 ... New York city. Dr. Singhvi,will provide an overview of ... the live presentation can be accessed via,the Company website ...
Cached Biology Technology:Aware, Inc. Announces Extension of Stock Repurchase Plan 2Transgenomic, Inc. Reports Third Quarter 2008 Results 2Transgenomic, Inc. Reports Third Quarter 2008 Results 3Transgenomic, Inc. Reports Third Quarter 2008 Results 4Transgenomic, Inc. Reports Third Quarter 2008 Results 5Transgenomic, Inc. Reports Third Quarter 2008 Results 6Transgenomic, Inc. Reports Third Quarter 2008 Results 7
(Date:8/28/2014)... -- Scientists have identified the developmental on-off switch for ... produce more than two-thirds of the world,s naturally derived ... to see whether it is possible to manipulate this ... , The study, appearing August 28 in Cell ... molecule called cyclic-di-GMP and a larger protein called BldD ...
(Date:8/28/2014)... delivering compounds that could positively impact the ... be possible, thanks to researchers in Penn ... vaginal suppository made from the seaweed-derived food ... drug Tenofovir provides a woman-initiated, drug-delivery vehicle ... sexually transmitted infections during unprotected heterosexual intercourse, ...
(Date:8/28/2014)... Energy production systems are good examples of complex ... like a networkincluding water for cooling, transport to ... management. Every step in the network chain is ... all mutually dependent. A team of UK-based scientists ... previously explored. The findings have been published in ...
Breaking Biology News(10 mins):Small molecule acts as on-off switch for nature's antibiotic factory 2Small molecule acts as on-off switch for nature's antibiotic factory 3Sensory-tested drug-delivery vehicle could limit spread of HIV, AIDS 2Sensory-tested drug-delivery vehicle could limit spread of HIV, AIDS 3Inter-dependent networks stress test 2
... urgent research in the field of Atrial Fibrillation, cardiologists from ... the European Heart House, headquarters of the European Society of ... people in the European Union. Its incidence increases in an ... year olds will develop AF during his or her life ...
... of the Blue Tongue virus has been created by WMG ... biologists devise new ways to combat the virus and protect ... of Warwick researchers based their model on data provided by ... University. The Warwick team used rapid prototyping technology, normally ...
... the heart,s earliest origins. Now, they have pinpointed a new, ... cardiomyocytes, or heart muscle cells. These stem cells, located in ... of being able to regenerate injured heart tissue. ... on June 22, comes on the heels of parallel cardiac ...
Cached Biology News:EHRA-AFNET summit on AF 2Engineers create 3-D model to help biologists combat blue tongue virus 2New source of heart stem cells discovered 2New source of heart stem cells discovered 3New source of heart stem cells discovered 4
N,N'-Methylene-bis-acrylamide, Ultra Pure...
Bovine Calf Serum...
Chicken polyclonal to ytzF ( Abpromise for all tested applications). Antigen: Full length protein...
...
Biology Products: